Literature DB >> 6352937

Antibodies to cytoplasmic intermediate filaments in rheumatic diseases.

P Kurki, T Helve, I Virtanen.   

Abstract

Antibodies to 2 types of cytoplasmic intermediate filaments (IMF)--vimentin and cytokeratin filaments--were assayed in sera from various rheumatic diseases by indirect immunofluorescence using cultured human embryonic fibroblasts and an epithelial cell line, PtK 2, as substrates. These antibodies belonged mainly to the IgM class and were detected in most of the sera. Vimentin filament antibodies of IgG or IgA class were frequent in Sjögren's syndrome (43%). Antibodies to another type of IMF, cytokeratin filaments, were also more prevalent in Sjögren's syndrome (64%) than in systemic lupus erythematosus (50%), rheumatoid arthritis (46%) and other hospital patients (8%). Our results show that intermediate filaments are a major target for autoantibodies in rheumatic diseases, especially in Sjögren's syndrome. The presence of intermediate filament IgA antibodies suggest that the stimulus for their production lies at epithelial surfaces.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352937

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  26 in total

1.  Antibodies to T- and L-isoforms of the cytoskeletal protein, fimbrin, in patients with systemic lupus erythematosus.

Authors:  E C De Mendonca Neto; A Kumar; N A Shadick; A M Michon; P Matsudaira; R B Eaton; P Kumar; P H Schur
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 2.  The cytoskeleton and its importance as a mediator of inflammation.

Authors:  K R Rogers; C J Morris; D R Blake
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

3.  Antibodies to neurofilament protein in retinitis pigmentosa.

Authors:  G M Galbraith; D Emerson; H H Fudenberg; C J Gibbs; D C Gajdusek
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Serum antibodies against central nervous system proteins in human demyelinating disease.

Authors:  J Newcombe; S Gahan; M L Cuzner
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

5.  Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study.

Authors:  B Dasgupta; O Duke; V Kyle; D G Macfarlane; B L Hazleman; G S Panayi
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

6.  Antibodies to intermediate filaments in polymyalgia rheumatica/giant cell arteritis: do they reflect the underlying disease activity rather than the acute phase response?

Authors:  I Monteagudo; V Corrigall; G S Panayi; G Pountain; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

7.  Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  Y Yang; J Fujita; S Bandoh; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Ishida
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

8.  Human vimentin autoantibodies preferentially interact with a peptide of 30kD mol. wt, located close to the amino-terminal of the molecule.

Authors:  A Alcover; C Hernández; J Avila
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

9.  Multiple autoantigen binding capabilities of mouse monoclonal antibodies selected for rheumatoid factor activity.

Authors:  R L Rubin; R S Balderas; E M Tan; F J Dixon; A N Theofilopoulos
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

10.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.